Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2017-07-04
Target enrollment:
Participant gender:
Summary
This study evaluates the value of bortezomib in combination with specified chemotherapies for
the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth.